These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21270111)

  • 1. Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition.
    Armstrong JL; Corazzari M; Martin S; Pagliarini V; Falasca L; Hill DS; Ellis N; Al Sabah S; Redfern CP; Fimia GM; Piacentini M; Lovat PE
    Clin Cancer Res; 2011 Apr; 17(8):2216-26. PubMed ID: 21270111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma.
    Hill DS; Martin S; Armstrong JL; Flockhart R; Tonison JJ; Simpson DG; Birch-Machin MA; Redfern CP; Lovat PE
    Clin Cancer Res; 2009 Feb; 15(4):1192-8. PubMed ID: 19228725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy.
    Hiscutt EL; Hill DS; Martin S; Kerr R; Harbottle A; Birch-Machin M; Redfern CP; Fulda S; Armstrong JL; Lovat PE
    J Invest Dermatol; 2010 Sep; 130(9):2250-8. PubMed ID: 20520630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
    Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
    Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.
    Selimovic D; Porzig BB; El-Khattouti A; Badura HE; Ahmad M; Ghanjati F; Santourlidis S; Haikel Y; Hassan M
    Cell Signal; 2013 Jan; 25(1):308-18. PubMed ID: 23079083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress.
    Lovat PE; Corazzari M; Armstrong JL; Martin S; Pagliarini V; Hill D; Brown AM; Piacentini M; Birch-Machin MA; Redfern CP
    Cancer Res; 2008 Jul; 68(13):5363-9. PubMed ID: 18593938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting GRP78 to enhance melanoma cell death.
    Martin S; Hill DS; Paton JC; Paton AW; Birch-Machin MA; Lovat PE; Redfern CP
    Pigment Cell Melanoma Res; 2010 Oct; 23(5):675-82. PubMed ID: 20546536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
    Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
    Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells.
    Armstrong JL; Flockhart R; Veal GJ; Lovat PE; Redfern CP
    J Biol Chem; 2010 Feb; 285(9):6091-100. PubMed ID: 20022965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
    Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
    Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of melanoma cells selective apoptosis induced by a photoactive NADPH analogue.
    Rouaud F; Boucher JL; Slama-Schwok A; Rocchi S
    Oncotarget; 2016 Dec; 7(50):82804-82819. PubMed ID: 27756874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
    Periyasamy-Thandavan S; Jackson WH; Samaddar JS; Erickson B; Barrett JR; Raney L; Gopal E; Ganapathy V; Hill WD; Bhalla KN; Schoenlein PV
    Autophagy; 2010 Jan; 6(1):19-35. PubMed ID: 20110775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance.
    Serasinghe MN; Missert DJ; Asciolla JJ; Podgrabinska S; Wieder SY; Izadmehr S; Belbin G; Skobe M; Chipuk JE
    Oncogene; 2015 Feb; 34(7):857-67. PubMed ID: 24608435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.
    Kim KW; Moretti L; Mitchell LR; Jung DK; Lu B
    Clin Cancer Res; 2009 Oct; 15(19):6096-105. PubMed ID: 19773376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway.
    Li Y; Luo P; Wang J; Dai J; Yang X; Wu H; Yang B; He Q
    Toxicol Appl Pharmacol; 2014 Jan; 274(2):319-27. PubMed ID: 24321340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.
    Goodall ML; Wang T; Martin KR; Kortus MG; Kauffman AL; Trent JM; Gately S; MacKeigan JP
    Autophagy; 2014 Jun; 10(6):1120-36. PubMed ID: 24879157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.
    Garandeau D; Noujarède J; Leclerc J; Imbert C; Garcia V; Bats ML; Rambow F; Gilhodes J; Filleron T; Meyer N; Brayer S; Arcucci S; Tartare-Deckert S; Ségui B; Marine JC; Levade T; Bertolotto C; Andrieu-Abadie N
    Mol Cancer Ther; 2019 Feb; 18(2):289-300. PubMed ID: 30482853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
    Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA
    Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
    Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
    Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.
    Fang H; Harned TM; Kalous O; Maldonado V; DeClerck YA; Reynolds CP
    Clin Cancer Res; 2011 Nov; 17(22):7093-104. PubMed ID: 21933888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.